Advertisement
CDNA vs RPID
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a StrongBuy and RPID is a Hold.
Aroon Indicator for CDNA shows an upward move is likely
CDNA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 207 similar instances where the Aroon Indicator showed a similar pattern. In 185 of the 207 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CDNA as a result. In 82 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in 238 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for CDNA turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 37 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
CDNA broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.599) is normal, around the industry mean (64.450). P/E Ratio (32.750) is within average values for comparable stocks, (2.086). CDNA's Projected Growth (PEG Ratio) (48.410) is very high in comparison to the industry average of (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.146) is also within normal values, averaging (9.775).
RPID's RSI Indicator ascends from oversold territory
The RSI Oscillator for RPID moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In 28 of the 32 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RPID just turned positive on September 23, 2026. Looking at past instances where RPID's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPID advanced for three days, in 175 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
RPID may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPID declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for RPID entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.307) is normal, around the industry mean (2.923). P/E Ratio (-0.735) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.465) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. RPID’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CDNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | |
SMR RATING 1..100 | 34 | |
PRICE GROWTH RATING 1..100 | 34 | |
P/E GROWTH RATING 1..100 | 4 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CDNA | RPID | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 79% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 80% | N/A |
| Momentum ODDS (%) | 2 days ago 84% | N/A |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| Advances ODDS (%) | 2 days ago 83% | about 1 month ago 79% |
| Declines ODDS (%) | 15 days ago 86% | 9 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CDNA’s FA Score shows that 1 FA rating(s) are green while RPID’s FA Score has 1 green FA rating(s).
- CDNA’s FA Score: 1 green, 4 red.
- RPID’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CDNA’s TA Score shows that 3 TA indicator(s) are bullish while RPID’s TA Score has 4 bullish TA indicator(s).
- CDNA’s TA Score: 3 bullish, 5 bearish.
- RPID’s TA Score: 4 bullish, 2 bearish.
Price Growth
CDNA (@Medical Specialties) experienced а +9.35% price change this week, while RPID (@Medical/Nursing Services) price change was -0.13% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
Reported Earning Dates
CDNA is expected to report earnings on Oct 29, 2026.
RPID is expected to report earnings on Nov 06, 2026.
Industries' Descriptions
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
RPID and
Correlation & Price change
A.I.dvisor tells us that RPID and ISRG have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RPID and ISRG's prices will move in lockstep.
| Ticker / NAME | Correlation To RPID | 1D Price Change % | ||
|---|---|---|---|---|
| RPID | 100% | +5.77% | ||
| ISRG - RPID | 30% Poorly correlated | -2.26% | ||
| QDEL - RPID | 28% Poorly correlated | -0.91% | ||
| CDNA - RPID | 27% Poorly correlated | +2.23% | ||
| GH - RPID | 27% Poorly correlated | +2.50% | ||
| ALC - RPID | 26% Poorly correlated | -0.59% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ORBX | 37.93 | 1.65 | +4.56% |
| Global X Space Tech ETF (ORBX) | |||
| BASV | 30.70 | 0.16 | +0.53% |
| Brown Advisory Sustainable Value ETF (BASV) | |||
| VYLD | 31.24 | 0.11 | +0.34% |
| Inverse Vix Short-Term Futures Etns Due March 22, 2045 | |||
| CGCV | 33.15 | 0.01 | +0.03% |
| Capital Group Conservative Equity ETF (CGCV) | |||
| APLZ | 27.94 | -5.83 | -17.26% |
| Tradr 2X Short APLD Daily ETF (APLZ) | |||